Furthermore, a recent abstract found that DCs pulsed with Profilin-1 (Pfn1) peptides slowed the growth of subcutaneous RCC tumors in murine orthotopic models and thus may hold promise as a monotherapy or ICI-combination regimen [205]. The gene discussed is PFN1; the disease is renal cell carcinoma.